[Malignant lymphoma].
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced; D008223:Lymphoma / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009367:Neoplasm Staging; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D012075:Remission, Spontaneous; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate
Maligne Lymphome.